Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Prospective, multicenter trial will evaluate a novel preservation technique utilizing the Paragonix SherpaPak® for DCD (Donation after Circulatory Death) hearts. Paragonix Technologies and UW...
-
Eledon to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at ATC
-
WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Paragonix Technologies, a pioneer in organ transplant technologies and services, announces utilization of the Paragonix LIVERguard® Donor Liver...
-
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
-
Transplants.org launches to guide transplant patients, caregivers and families with clinician-backed education, navigation tools and outcomes data.
-
Paragonix Technologies will feature oral presentations and poster sessions at ISHLT 2026, showcasing clinical data related to its heart and lung preservation devices.The extensive research being...
-
Austin, United States, March 20, 2026 (GLOBE NEWSWIRE) -- Organ Preservation Market Size & Growth Analysis: According to SNS Insider, The Organ Preservation Market size is valued at USD 311.36...
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
-
TolerogenixX´ MIC therapy receives EMA PRIME designation; up to 10-year follow‑up data support sustained safety and reduced immunosuppression
-
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation